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ABSTRACT 
 
BACKGROUND 
Conventional biomarkers in thyroid cancer (thyroglobulin, calcitonin, CEA) are not disease-specific 
and can fluctuate in advanced disease, making interpretation difficult. Cell-free circulating tumour 
DNA (ctDNA) has been shown to be a useful biomarker in other solid tumours. We hypothesized that 
ctDNA is a potential candidate for a disease-specific, minimally invasive biomarker with the potential 
to guide personalised treatment plans in thyroid cancer. This proof-of-concept study was a multi-
mutational analysis of ctDNA to test this hypothesis in patients with advanced thyroid cancer over 
multiple time-points. 
 
METHODS 
Mutational analysis of archival tumour tissue was performed on an NGS platform using a validated 
gene panel targeted to known cancer hotspots. Custom Taqman assays for discovered variants were 
designed for plasma ctDNA testing using digital droplet PCR. Concentrations of detected ctDNA were 
correlated with conventional biomarker concentration and axial imaging status defined by RECIST 
criteria.  
 
RESULTS 
Tumours were obtained from 51 patients, with the following histologies: 17 papillary, 15 follicular, 
15 medullary, 3 poorly differentiated and 1 anaplastic. Variants were detected in 42 (82%) of the 
tumour tissue samples. Detected rates of variants in genes per histological subtype were broadly in 
line with published data. Plasma was assayed for ctDNA in 190 samples from 42 patients. ctDNA was 
detected in 67% of tested patients. Earlier detection of disease progression was noted in 2 patients 
with medullary thyroid cancer (MTC). In a further 2 cases, conventional biomarkers were not 
detected due to anti-thyroglobulin antibodies and de-differentiated disease, yet ctDNA was detected 
and also showed increasing levels prior to radiologically-confirmed disease progression. Changes in 
ctDNA concentration were noted to occur earlier than for conventional markers in response to 
disease progression in multiple patients receiving targeted therapies, raising the possibility that 
these patients might have been spared from ongoing ineffective, toxic therapy.  
 
CONCLUSION 
Detectable levels of ctDNA were found in the plasma of the majority of patients with advanced 
thyroid cancer. Sub-analysis suggests that ctDNA measurement may offer superiority over 
conventional markers in several clinically relevant scenarios. These include earlier detection of 
progression in MTC; use as an alternative biomarker when conventional markers are not available 
due to auto-antibodies or de-differentiated disease; and more rapid assessment of disease status in 
response to targeted therapies, thereby potentially allowing prompter discontinuation of futile 
therapies. These early results support the hypothesis that ctDNA may be a clinically useful biomarker 
in thyroid cancer and this will be tested in a planned multi-centre study. 
 
 INTRODUCTION 
 
Serum thyroglobulin (Tg) concentration is used as a biomarker in differentiated thyroid cancer (DTC) 
for detection of residual thyroid tissue, persistent disease and relapse. However, it has several 
drawbacks that limit its clinical utility. Detection of thyroglobulin in plasma is tissue-specific, not 
cancer-specific, and its secretion by both benign and malignant tissue reduces its specificity. In 
addition, thyroglobulin levels do not accurately represent tumour burden in circumstances when 
anti-Tg auto-antibodies are present, affecting up to 25% of patients (1, 2), or in de-differentiated 
carcinoma. Furthermore, Tg is more difficult to interpret as a biomarker in patients treated with 
lobectomy or who have not undergone radio-iodide ablation. In medullary thyroid cancer (MTC), 
calcitonin and carcinoembryonic antigen (CEA) are used as alternative biomarkers. These are also 
not cancer-specific and can be slow to reflect changes in disease status.   
 
Serial imaging is likewise used for monitoring and detection of disease progression. However, small 
volume changes may not be readily visible on anatomical or functional imaging, which can lead to a 
significant lag time in detecting progression. CT scanning, a frequently used modality, leads to 
repeated exposure of patients to ionising radiation which, in patients with a relatively indolent 
disease, is an important consideration. There is also an associated financial cost of serial imaging. 
 
Given these limitations, new biomarkers are required to assist in the clinical management of thyroid 
cancer. A biomarker that could detect progression earlier with a high degree of specificity would be 
extremely useful. One that better identifies aggressive subtypes, detects recurrence at an earlier 
time-point and predicts response to therapies would be especially desirable. 
 
Technological advances in genomics, such as next-generation sequencing (NGS) and digital 
Polymerase Chain Reaction (dPCR), allow detection of sequence-specific DNA at extremely low 
concentrations within clinically appropriate time and cost constraints. These advances paved the 
way for circulating tumour DNA (ctDNA) to emerge as a viable cancer biomarker. There is now 
substantial evidence of clinical utility in a variety of cancers (3-5) and, in fact, one ctDNA assay has 
received regulatory approval for use in the detection of an EGFR variant in non-small cell lung cancer 
(6). Although the exact mechanisms by which ctDNA enters the circulation are poorly described, it 
likely originates from either leakage from cells undergoing necrosis and apoptosis or active secretion 
(7-9). 
 
Using ctDNA as a biomarker has several potential advantages. Detection of oncogenic mutations 
renders its presence in plasma extremely specific for cancer cells compared to conventional 
biomarkers. Traditional solid tumour biopsies may present DNA that is not fully representative of the 
mutational landscape due to intra-tumour heterogeneity (10-12). In contrast, ctDNA may provide a 
more complete representation of the mutational landscape present across the entirety of the 
patient’s disease burden. Obtaining tumour tissue for DNA extraction is not always possible and may 
be associated with significant risk, whereas ctDNA is extracted from plasma samples at almost no 
risk to the patient. 
 
A small study focussing on colorectal cancer (13) highlighted the potential use of ctDNA to identify 
patients with residual micro-metastatic disease after surgery. There has since been a drive towards 
establishing detection of ctDNA levels as a biomarker for molecular residual disease (MRD) in 
patients following primary treatment. There is now mounting evidence to support this approach, 
using ctDNA as a “test of cure” in early solid, non-metastatic cancers in several tissues including 
breast (3), colon (14) and lung (15, 16).  
 
Recent studies have shown that ctDNA is detectable in thyroid cancers of different subtypes (17-21) 
but have examined only a single variant or a single time point. With this in mind, the hypothesis of 
this study was that ctDNA, if detectable, would prove to be a predictive and prognostic biomarker 
for thyroid cancer, permitting individualisation of treatment. The primary aim of this proof-of-
concept study was to conduct a comprehensive, multi-mutational analysis in ctDNA across a range of 
thyroid cancer subtypes over multiple time points. Secondary aims were to correlate changes in 
ctDNA concentration with currently used biomarkers (Tg, Calcitonin, CEA) and CT imaging, with the 
ultimate goal of generating evidence that ctDNA detected disease progression either earlier or more 
reliably than current biomarkers. 
 
 
METHODS 
 
Ethical Approval 
Patients were recruited by the senior author (KN) from a thyroid cancer clinic at The Royal Marsden 
Hospital between December 2015 and September 2016. This study received approvals from the 
institutional review board (CCR4343) and the West of Scotland Research Ethics Service (WoSRES) 
committee (15/WS/0148). All patients provided written, informed consent.  
 
Study design 
Archival tumours were sequenced using an NGS platform for genetic variant discovery. Time 
between tumour excision and study entry is shown for each patient in supplementary table 1. 
Plasma samples were collected from patients at baseline, and 3-monthly thereafter. Results 
obtained from the tissue NGS sequencing were used to guide the design of bespoke digital droplet 
PCR (ddPCR) assays for detection of the identified variants in the plasma cell-free DNA (cfDNA). 
Analysis of the plasma cfDNA with the appropriate ddPCR assay allowed the variant(s) to be 
identified and to be tracked sequentially over time. 
 
DNA extraction – Tumour 
Archival formalin-fixed, paraffin-embedded (FFPE) tissue blocks were used for extraction where 
possible. If FFPE blocks were not available, then haematoxylin and eosin-stained (H&E) slides were 
used as an alternative. From the FFPE blocks, six slides were cut by microtome: one H&E slide was 
reviewed by a specialist pathologist to identify the tumour and comment on cellularity and tumour 
content, and five 10 µM non-stained slides were used for DNA extraction. Non-stained slides were 
de-waxed using established protocols. The H&E slide was used as a guide for manual macro-
dissection of tissue from the non-stained slides. DNA was extracted using a spin column-based 
nucleic acid purification kit (Qiagen QIAamp DNA FFPE kit, Qiagen, Hilden, Germany). DNA clean-up 
was performed on samples with a concentration of <5 ng/µL using a DNA clean and concentrator kit 
(Zymo Research, CA, USA). 
 
Library preparation 
Library preparation was performed using the KAPA HyperPlus kit (Roche, Switzerland). DNA sample 
concentrations were quantified using a Qubit Fluorometer (ThermoFisher, Massachusetts, USA). The 
input amount of DNA per sample was 200 ng if the extracted sample concentration was >5 ng/µL 
with an average peak fragment size of >1000 b.p. length. If the average peak fragment size was 
<1000 b.p., then 400 ng was used to account for the higher fragmentation. When extracted DNA 
concentration did not allow for the approach described above, then a low input (50 ng) protocol was 
used. Dual size selection and short-cycle amplification clean-up were performed using AMPure XP 
clean-up beads (Beckman Coulter, Brea, CA, USA). Library amplification was performed using 6 cycles 
of PCR for the 200 and 400 ng samples or 10 cycles for the 50 ng protocol. All tumour samples had 
matched buffy coat samples sequenced concurrently for variant calling to permit filtering of 
germline variants.  
 
Sequencing 
A clinically validated capture-based target enrichment gene panel was used (Supplementary Table 
2). This panel was targeted to known cancer mutation hotspots, present in a wide array of solid 
tumours. Nimblegen Capture KAPA HyperPlus kits (Roche) were used for panel hybridisation. Quality 
control after hybridisation and PCR amplification were performed using TaqMan quantitative PCR 
prior to sample sequencing. Samples were sequenced on either a NextSeq or MiSeq platform 
(Illumina, San Diego, USA) according to manufacturer’s user guides 
 
Bioinformatics 
Sequencing output files were demultiplexed using Bcl2fastq2 v.2.19 (Illumina) and aligned to 
reference genome GRCh37 using BWA-mem v.0.7.12 software. Data were filtered through an in-
house pipeline that included GATK Mutect2 version 3.5.0 (Broad Institute, Cambridge, 
Massachusetts) for single nucleotide variant (SNV) and insertion/deletion (Indel) annotation, and 
Manta v.0.29.6 for structural variants. Additional in-house filters applied to variant calling included 
deletion and amplification thresholds of <0.5x and >2.4x, respectively.   
 
DNA extraction - Blood 
20 mL of peripheral blood was collected from patients in cell-free DNA Blood Collection Tubes 
(Streck, La Vista, USA). Samples were centrifuged twice for 10 minutes at 1600g. Plasma was 
aliquoted and stored at -80°C. Cell-free DNA was extracted from approximately 4 mL of plasma using 
the QIAsymphony DSP Circulating DNA Kit (Qiagen, Hilden, Germany) on a QIAsymphony SP 
platform.  
  
Plasma genotyping 
Plasma samples were genotyped using the QX-200 droplet digital PCR system (Bio-Rad, California, 
USA). Custom Taqman assays were used (Bio-Rad & Applied Biosystems, Thermo Scientific) 
according to the variants discovered from tumour tissue sequencing. For each plasma time-point, 
10.45 µL of DNA was placed per well in at least 2 wells and interrogated with the custom assays. 
Mean cfDNA concentration of samples was 0.43 ng/μL (range 0.079 – 1.47). For each patient-specific 
assay one No Template Control (NTC), one wild-type control (fragmented Promega DNA at 1 ng/µL) 
and one positive control (patient’s own tumour DNA) were used. All custom assays detected their 
target variant in tumour controls with very high correlation (R2 = 0.92) between NGS and dPCR 
tumour allele frequency (AF) (Supplementary Figure 1 ). 
 
cfDNA samples were emulsified on a droplet generator. Emulsified PCR reactions were run on 96-
well plates on a C1000 Touch Thermal Cycler (Bio-Rad), incubating the plates at 95°C for 10 min, 
followed by 40 cycles of 94°C for 30 s and 60°C for 60 s, then by a 10-min incubation at 98°C. The 
temperature ramp increment was 2.0°C/s for all steps. Samples were read on a QX-200 ddPCR 
droplet reader as per manufacturer’s guidelines. Results were analysed using Bio-Rad’s QuantaSoft 
software v.1.7.4, and individual cut-offs established for each assay. A minimum of 20,000 droplets 
across both wells was required for a valid test. A minimum of 2 single FAM positive droplets with a 
number of double positive droplets lower than single FAM droplets was required to make a positive 
call. If no positive result was obtained in 2 wells, then the assay was repeated for a further 2 wells. 
 
  
Standard Biomarker Assays 
The Access Thyroglobulin and Thyroglobulin Antibody II chemiluminescent immunoassays (Beckman 
Coulter, Brea, CA, USA) were used for Tg and anti-Tg antibody quantification, respectively. Calcitonin 
assay was done with the LIAISON® Calcitonin II-Gen one-step sandwich chemiluminescence 
immunoassay (DiaSorin, Saluggia, Italy). Quantitative CEA assaying was performed using the 
ARCHITECT chemiluminescent microparticle immunoassay (Abbott Laboratories, IL, USA).  
 
Imaging 
Contrast-enhanced CT scanning was used for axial imaging in this study, with views obtained of the 
head, neck, thorax, abdomen (liver imaging was initially triple phase at baseline, dual phase 
thereafter) and pelvis. Progression was defined as per RECIST criteria (22) 
 
 
RESULTS 
Tumour tissue mutational analysis 
52 patients were recruited to the study (Figure 1). Tissue was not available for analysis in one 
patient. The histological subtypes of the final 51 patients were as follows: papillary (n = 17), follicular 
(15), medullary (15), poorly differentiated (3) and anaplastic (1). The clinical characteristics are 
summarised in Table 1 and shown in more detail in Supplementary Table 2. Tissue blocks were 
retrieved for DNA extraction in 50 cases. In one case, blocks were not available and DNA extraction 
was performed from H&E stained slides. We aimed to obtain a minimum of 3 plasma time-points, 
sampled every 3 months per patient where possible, and a mean of 5 time-points was achieved. A 
total of 190 plasma samples were assayed.  
In total, 58 variants were discovered in 42 patients. At least one variant was detected in 82% of our 
patient cohort. All variants were either Single Nucleotide Variants (SNVs) or small insertion/deletions 
(Indels). A heatmap illustrating discovered variants is shown in Figure 2 (see supplementary table 3 
for a full list of variants).  
Histological sub-analysis of variants (Figure 3) showed that for PTC, the frequency of variants found 
in each mutated gene was broadly in line with rates previously published by the TCGA (23) as well as 
the mutated genes listed by the Catalogue of Somatic Mutations in Cancer (COSMIC) (24), as shown 
in figure 4a. All BRAF variants detected were the c.1799T>A (p.V600E) variant, which represented 13 
of the 21 (61%) mutations discovered in the papillary subset. The most frequently mutated gene in 
the follicular cohort was NRAS, contributing 20% of the total variants, with similar rate to that seen 
in the COSMIC database (figure 4b). The mutation rates in genes obtained in our study compared to 
COSMIC for MTC are shown Error! Reference source not found.4c. The most commonly detected 
variant in the medullary cohort was RET c.2753T>C which accounted for 7 of 15 (46%) in 
concordance with other published data series (25). A RET mutation was entirely specific for a 
medullary histology in our cohort. 
Nine patients had 2 or more driver mutations, and all these patients had metastatic disease. 
Histological subtypes associated with more aggressive disease, such as Hürthle cell and PDTC were 
over-represented in this group.  
Plasma ctDNA detection 
The primary end-point for the study was detection of plasma ctDNA, and in our cohort ctDNA was 
detected in at least one plasma time point in 67% (n=28/42) of patients. Based on histology, the 
detection rate was higher in MTC compared to PTC and FTC (Table 2). However, five patients had no 
identifiable macroscopic disease throughout the study, and negligible levels of conventional 
markers. If these patients were excluded from the analysis the detection rates were more balanced 
across the histologies and the overall detection rate increased to 76% (Table 2). The detection rate 
was highest in patients with metastatic disease (79%) compared to those with local recurrence (33%) 
or no macroscopic disease (0%)  
The secondary endpoint of the study was correlation of ctDNA with currently used biomarkers. In 
this cohort, a clear overall trend was observed where detected plasma ctDNA concentrations 
correlated with Tg, calcitonin and CEA. Statistical analysis revealed a significant positive correlation 
(r values >0.5) between concentrations of ctDNA and those of conventional biomarkers.  
 
Scenarios where ctDNA may offer superiority over conventional biomarkers 
Serial serum analysis demonstrated that ctDNA markers may provide clinically important advantages 
over current plasma biomarkers in a number of cases (Figures 5, 6 and 7). These include detection of 
ctDNA in the absence of other markers, earlier changes in ctDNA levels reflective of disease status 
and more rapid detection of change in disease status when the patient is started on targeted 
therapies.  
 
Figure 5 shows ctDNA levels in two patients who had no usefully detectable levels of conventional 
biomarkers. One patient (Fig. 5a) had no Tg due to anti-Tg antibodies, and the other (Fig. 5b) had 
none as a result of severe tissue de-differentiation in anaplastic disease. Both patients had 
detectable ctDNA demonstrating upward trends before progression was detected with axial imaging.  
 
In three patients with MTC who had evidence of progressive disease (clinically and on CT imaging) 
during surveillance, we observed earlier upward trends in ctDNA than the corresponding 
conventional biomarker (figures 6a-c). This could allow for earlier prediction of disease progression.  
 
In several patients on targeted therapy for progressive disease, we observed changes in ctDNA titres 
that were more marked/rapid than conventional markers. This potentially allows for both earlier and 
more confident prediction of response to therapy (Figures 7a-d). Figures 7a-c illustrate more 
significant or earlier increases in ctDNA, likely reflecting development of resistance to the targeted 
therapy. Figure 7d demonstrates the reverse: an extremely large decrease in ctDNA levels is seen 
after starting effective TKI therapy.  Conventional biomarkers were not able to track these changes 
so responsively. 
 
In patients with 2 variants detected in the tumour which were tracked in the plasma, we observed 
significant differences in the levels of one variant compared to the other (Figures 5a, 7b, 7c). In one 
patient (Fig 7b), the TP53 c.1009C>T variant was strongly positive in all samples, whereas the TP53 
c.742C>T variant was not detected in any plasma samples. In two other patients (Figs 5a & 7c), both 
variants are initially seen to monitor disease burden. However, the subsequent progression of 
disease is tracked by only one variant. Differential levels of alternative variants may provide insight 
into tumour evolution.  
 
  
DISCUSSION 
The aim of our study was to investigate the potential role of comprehensive multi-variant mutational 
analysis using next generation sequencing and to report findings that provide support for the use of 
plasma ctDNA as a biomarker in thyroid cancer. Examining multiple genes in a variety of thyroid 
cancer histologies, ctDNA was detected in 67% of patients in this study. Within the cohort of 42 
patients in whom tumour variants were observed, 5 patients had no evidence of biochemical and 
structural disease throughout the study period. Therefore, the overall sensitivity for ctDNA detection 
was 76% (Table 2) and is comparable to rates obtained in other, more aggressive, cancers such as 
lung and breast (26).  
Cote et al (20) recently evaluated the detection of a single variant, RET p.M918T, in the plasma of 
patients with MTC known to harbour this variant in their tumours. Their reported detection rate was 
only 32%. In our MTC cohort, the detection rate was much higher (85%, adjusted). Both the use of 
one genetic variant as a biomarker and a single time point analysis in the Cote study are likely to 
have been responsible for their lower detection rates. Interestingly, the rate of ctDNA detection was 
higher in patients with greater disease burden. This may also explain the higher detection rates for 
our study in MTC patients (79%, unadjusted) all of whom had metastatic disease compared to PTC 
patients (53%, unadjusted). Further, in the more aggressive histological sub-types (ATC and PDTC), 
ctDNA was always detected, although numbers were low.  
The rates of variants detected in the tumour tissue for this study were broadly in line with published 
data and those of the TCGA and COSMIC databases.  In the COSMIC database, the gene most 
frequently observed to have variants in FTC is TERT. Our targeted gene panel did not include this 
gene, so TERT mutations were not detectable in our study.  
 
Analysis of serial serum samples demonstrated a clear trend where detected plasma ctDNA 
concentrations correlated with conventional biomarkers; Tg, calcitonin and CEA levels, and with 
disease status (disease response/progression) defined by axial imaging. Although the current study 
was primarily designed to evaluate ctDNA as a potential biomarker in thyroid cancer, our data 
provide early indications that ctDNA represents an important complementary assay and could offer 
several advantages over conventional markers.  
 
ctDNA may prove to be an important biomarker of disease burden and response to treatment in 
patients when thyroglobulin cannot be used for monitoring, such as in patients with significant anti-
thyroglobulin antibodies, and in de-differentiated thyroid cancers. In our study, one patient had 
undetectable thyroglobulin and significant anti-thyroglobulin antibodies at all time-points, yet ctDNA 
was detected for two variants in this patient’s plasma and exhibited an upward trend in the BRAF 
variant coinciding with disease progression later confirmed on subsequent axial imaging (figure 5a). 
In a further patient with anaplastic carcinoma, the conventional biomarker (Tg) was not detectable, 
presumably due to tumour de-differentiation (figure 5b). However, ctDNA was detectable at all time 
points and exhibited an upward trend consistent with disease progression which was later confirmed 
on axial imaging, and the patient subsequently died from the disease. Therefore, ctDNA may 
represent an important biomarker in anaplastic and de-differentiated thyroid cancers, particularly if 
effective therapies become available in the future.  
 
In this study, ctDNA levels appear to change more rapidly in response to a change in disease status 
than conventional markers and may offer a more contemporaneous measure of response to 
treatment. In multiple patients, we observed an upward trend in ctDNA earlier (4-8 months earlier) 
than the corresponding conventional biomarker (figure 6), or a significantly more marked increase in 
levels (figure 7a-c), allowing not only for earlier but also more confident prediction of disease 
progression. These trends were later confirmed by axial imaging demonstrating disease progression.  
 Assessing early biological response to targeted therapy and ascertaining when resistance develops in 
patients with thyroid cancer has traditionally been difficult, and ctDNA could potentially assist in this 
setting. In several patients, we detected marked and rapid reduction of ctDNA levels (figures 5a, 7c, 
7d) shortly after starting systemic targeted therapy. The more rapid responses of ctDNA levels in 
response to targeted therapy seen in this study would be useful in gauging early response to 
treatment. On the other hand, this might be show greatest clinical value in detecting futility of 
therapy, thereby allowing prompt cessation of a potentially toxic but ineffective treatment. Further, 
development of resistance to treatment appears to be detected by ctDNA rises after the initial drop. 
It is evident that such changes in response cannot always to be monitored by conventional 
biomarkers (Figs 5a, 6b, 7b-d). Prompt detection of resistance would allow the timely addition of 
alternative therapeutic agents to overcome newly-developing resistance. These more rapid changes 
in ctDNA concentrations may reflect significant differences in biomarker half-lives, which may be as 
low as 2 hours in ctDNA (13) and up to 65 hours for thyroglobulin (27, 28). 
 
Much has been published on the dynamic mutational landscape of cancers as a result of subclonal 
evolution (10-12), but data are sparse in thyroid cancer. In 3 patients, there was a substantial 
difference between the trends in the two tracked variants in the ctDNA, which was not reflective of 
the differences in tumour allele frequencies seen in the NGS results. This discrepancy may reflect 
subclonal evolution, as the tumour tissue samples often pre-dated the plasma samples by many 
years (Supplementary table 1). Discordant results obtained in the plasma may reflect one subclone 
emerging as more dominant than another. This has implications for patient therapy: knowledge of a 
dominant subclone may influence choice of intervention.  
 
With the latest assays permitting consistent interpretation of sequencing at much higher read depth 
from significantly lower allele fractions, it is now feasible to sequence DNA extracted directly from 
plasma samples. We aim to apply this approach over serial plasma samples in thyroid cancer 
subtypes in order to track the changing mutational landscape without the need for repeated tissue 
biopsies. This may help overcome difficulties related to intra-tumour heterogeneity that is inherent 
in tissue biopsies. Further, several studies have demonstrated that ctDNA can be used to detect 
resistance-conferring mutations in both breast and lung cancer (29-31) and, although resistance 
mutations are not currently known in thyroid cancer, our study data suggest this is a feasible 
direction of study and warrants further investigation.  
 
CONCLUSION 
This study demonstrates that, using a multi-variant approach, a high proportion of patients with 
advanced thyroid cancer have detectable levels of ctDNA in their plasma. We observed correlation 
of ctDNA with conventional markers of disease in DTC. We suggest, based on our data, that ctDNA 
may be particularly useful when conventional markers are not helpful, for example in de-
differentiated disease or when anti-Tg antibodies render Tg an unreliable marker. ctDNA is, 
therefore, likely to complement current conventional biomarkers in the management of thyroid 
cancer. Further, our data suggest that ctDNA may predict disease progression earlier and more 
confidently than conventional markers, particularly in MTC. For patients on targeted therapies, 
ctDNA may offer a more rapid and reliable assessment of disease response, providing information on 
effectiveness of therapies and guiding drug selection. These early results are promising and ctDNA 
may prove to be a clinically useful biomarker in thyroid cancer. Further investigation with a larger 
sample size is required to confirm these initial findings. 
 
  
FIGURES AND TABLES 
 
Figure 1 – CONSORT diagram of study 
 
Clinical Characteristics 
 Demographics   
Median Age, years (Range) 61 (27 – 81) 
Female, n (%) 
 
26 (51) 
Tumour Histology   
Papillary, n (%) 17 (34) 
Follicular 
 
15 (29) 
Poorly Differentiated 3 (6) 
Anaplastic 
 
1 (2) 
Medullary 
 
15 (29) 
Disease Status at study entry 
No structural disease, n (%) 6 (12) 
Local recurrence 2 (4) 
Distant metastasis 43 (84) 
Table 1 – Summary of patient clinical characteristics  
 
 Figure 2 - Mutation heat map from study cohort 
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THY005 c.1799T>A Papillary
THY006 c.182A.G Papillary
THY018 c.1799T>A Papillary
THY022 c.1799T>A Papillary
THY024 c.1799T>A c.3061T>C Papillary
THY032 c.1799T>A Papillary
THY035 c.182A.G c.*50G>A c.28G>T Papillary
THY038 c.1799T>A Papillary
THY039 c.1799T>A c.6397G>C c.49G>A Papillary
THY042 c.1799T>A Papillary
THY043 c.1799T>A Papillary
THY046 c.1799T>A Papillary
THY049 c.1799T>A c.61G>A Papillary
THY050 c.1799T>A Papillary
THY017 c.1799T>A Papillary (Tall Cell)
THY010 c.181C>A Follicular
THY011 c.814G>A c.328C>T Follicular
THY012 c.181C>A c.1800_1801delinsTT Follicular
THY021 c.182A>G Follicular
THY036 c.182A>G Follicular
THY028 c.182A>G Follicular  
THY008 c.5796G>T Follicular (Hurthle)
THY027 x 3 Follicular (Hurthle)
THY044 c.5746C>T c.634delT Follicular (Hurthle)
THY047 c.634+5G>C Follicular (Hurthle)
THY030 c.182A>G Poorly differentiated
THY045 c.637C>T c.548dupA c.3404C>T Poorly differentiated
THY033 c.473G>A c.-21G>A c.1377G>A Anaplastic
THY041 c.2671T>G Medullary (MEN 2a)
THY001 c.2753T>C Medullary 
THY002 c.1894_1899delGAGCTG Medullary 
THY003 c.2753T>C + c.881C>G Medullary 
THY009 c.2753T>C Medullary 
THY014 c.2753T>C Medullary 
THY015 c.2647delinsGC>TT Medullary 
THY016 c.2753T>C Medullary 
THY019 c.1799T>A Medullary 
THY020 c.182A>G Medullary 
THY023 c.2753T>C Medullary 
THY037 c.2647delinsGC>TT Medullary 
THY048 c.2753T>C Medullary 
THY053 Complex indel Medullary 
Total 14 13 6 6 3 2 2 2 2 1 1 1 1 1 1 1 1
(%) 24.1 22.4 10.3 10.3 5.2 3.4 3.4 3.4 3.4 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.7
  
 
Figure 3 –frequency of variants found in each cancer subtype per gene 
 
 
 
 
 
 
 
 
 
 
 
Histology (n) Detection Rate Adjusted 
Papillary (15) 53% 73% 
Follicular (10) 60% 60% 
Medullary (14) 79% 85% 
PDTC (2) 100% 100% 
ATC (1) 100% 100% 
Total (42) 67% 76% 
Table 2 – Detection rate: detection rates in patients of ctDNA in at least one plasma time point. Adjusted: detection rates adjusted for 5 
patients with no macroscopic disease and negligible conventional markers 
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SUPPLEMENTARY MATERIALS 
 
Supplementary table 1 – Clinical characteristics of enrolled patients 
 
 
 
 
 
Trial ID Sex
Age at study 
entry
TNM Staging at 
diagnosis
Tumour Histology Disease Status at study entry Location of metastasis, if present
Time: diagnosis 
to study entry 
(years)
THY005 F 62 T3 N0 M1 Papillary Distant Met Mediastinum, Lung 8
THY006 F 74 T4a Nx M1 Papillary Distant Met Lung, Mediastinum, Bone 15
THY018 F 61 T3 N0 M0 Papillary No Macroscopic Disease 1
THY022 F 64 T2 Nx M0 Papillary Distant Met Brain, Lung, Spine, Humerus 14
THY024 M 69 T4 N1 M0 Papillary Distant Met Thyroid Bed, Mediastinum, Pulmonary 12
THY032 F 46 T3 N1b M0 Papillary Distant Met Lung 5
THY035 M 74 T3 N1b M0 Papillary Distant Met Lung, Bone, Adrenal, Mediastinal, Local 2
THY038 F 47 T3 N0 M0 Papillary No Macroscopic Disease 1
THY039 F 71 T4b N0 M0 Papillary Distant Met Bone, Chest wall, Local nodal 18
THY042 M 58 T2 N0 M0 Papillary Distant Met Lung, Local Nodal 13
THY043 F 66 T1 N0 M0 Papillary Distant Met Lung, Mediastinum 6
THY046 F 57 T3 N1b M0 Papillary No Macroscopic Disease 3
THY049 M 56 T3 N1b M0 Papillary Local recurrence 1
THY050 M 27 T3 N1b M0 Papillary No Macroscopic Disease 6
THY051 M 60 T3 Nx M0 Papillary Distant Met Mediastinum, Supraclavicular Fossa 9
THY007 M 48 T3 N0 M0 Papillary (Tall  Cell) Distant Met Brain 6
THY017 M 46 T4a N1b M1 Papillary (Tall  Cell) Distant Met Lung, Spine 5
THY010 F 77 T3 Nx M0 Follicular Distant Met Lung 11
THY011 F 30 T3 N0 M0 Follicular Distant Met Lung, Brain, Bone, Nodal 3
THY012 M 72 T3 N0 M1 Follicular Distant Met Bone 8
THY021 F 78 T3 N0 M0 Follicular Local recurrence 1
THY034 M 64 T2 N0 M0 Follicular Distant Met Lung 3
THY036 M 56 T2 N1b M0 Follicular Distant Met Lung 5
THY040 M 73 T1b Nx M1 Follicular Distant Met Bone 1
THY028 F 61 T1b N0 M1 Follicular  Distant Met Lung, Bone 5
THY008 F 67 T2 Nx M0 Follicular (Hurthle) Distant Met Liver, Lung 6
THY013 F 81 T1b N0 M0 Follicular (Hurthle) Distant Met Thyroid Bed, Lung 21
THY026 M 74 T4 N0 M0 Follicular (Hurthle) Distant Met Lung, Renal, Mediastinal 9
THY027 M 51 T3 N1b M1 Follicular (Hurthle) Distant Met Lung 3
THY029 F 48 Tx Nx M1 Follicular (Hurthle) Distant Met Mediastinum, Spine, Lung 8
THY044 F 49 T3 N1a M1 Follicular (Hurthle) Distant Met Mediastinum, Liver, Bone 5
THY047 M 73 T3 N0 M0 Follicular (Hurthle) Distant Met Bone (rib) 5
THY031 F 70 T3 N0 M0 Poorly differentiated Distant Met Lung 4
THY045 F 67 T3 N1a M1 Poorly differentiated Distant Met Lung, Mediastinum 1
THY030 F 63 T2 N0 M0 Poorly differentiated Distant Met Liver, Brain, Local 9
THY033 M 66 T4b Nx M0 Anaplastic Distant Met Bone, Local, Mediastinum, Lung 1
THY001 M 54 T3 N1b M1 Medullary Distant Met Lung, Liver, Mediastinum 1
THY020 F 67 T2 N1b M0 Medullary Distant Met Spine 16
THY023 F 33 T3 N1b M1 Medullary Distant Met Liver, Mediastinum, Local nodal 1
THY053 F 75 T2 N1b M0 Medullary No Macroscopic Disease 11
THY002 M 45 T4a N1b M1 Medullary Distant Met Liver 2
THY003 F 71 Tx N1a M0 Medullary Local recurrence 3
THY009 M 59 T4a N1b M0 Medullary Distant Met Supraclavicular fossa 7
THY014 M 68 Tx Nx M0 Medullary Distant Met Mediastinal, pericardial 33
THY015 M 41 Tx N1b M1 Medullary Distant Met Lung, Liver, Brain 11
THY016 M 54 T2 N1a M1 Medullary Distant Met Liver, Spine, Lung, Local 14
THY019 M 28 T3 N1b M1 Medullary Distant Met Mediastinal, Liver, Bone 4
THY037 M 67 T2 N1b N0 Medullary Distant Met Bone, Liver, Lung, Mediastinal 29
THY048 F 30 Tx N1b M1  Medullary Distant Met Local Nodal, Lung, Bone, Breast, Liver, Mediastinum <1
THY041 M 32 T4a N1a M0 Medullary (MEN 2a) Distant Met Bone, Orbit, Tracheal 15
THY025 F 39 TxNxMx Medullary (MEN 2a) Distant Met Liver, Lung, Oesophageal, Spine 13
 Gene 
AKT1 
APC 
ARID1A 
ATM 
BRAF 
ARID1A 
ATM 
CDKN2A 
CDKN2B 
CTNNB1 
DOCK2 
EGFR 
ELMO1 
ERBB2 
ERBB4 
FBXW7 
HRAS 
IDH1 
IDH2 
JAK3 
KIT 
KRAS 
MAP2K1 
MAP2K2 
NOTCH 1 
NOTCH2 
NOTCH3 
NRAS 
PDGFRA 
PIK3CA 
PTEN 
RET 
ROS1 
SMAD4 
TCF7L2 
TP53 
UGT1A1 
VHL 
Supplementary Table 2 - List of Genes in Targeted Panel 
 
 
 
 
 
 
 
 
 
 
 
Trial ID GENE  PROTEIN HGVS TAF 
THY033 AKT1 n/a c.-21G>A 0.31 
THY039 AKT1 p.Glu17Lys c.49G>A 0.29 
THY039 APC p.Asp2133His c.6397G>C 0.32 
THY044 APC p.Gln1916Ter c.5746C>T 0.39 
THY012 ARID1A p.Gln601Ter c.1800GC>TT 0.34 
THY044 ATM p.Phe213fs c.634delT 0.71 
THY005 BRAF p.Val600Glu c.1799T>A Man 
THY017 BRAF p.Val600Glu c.1799T>A 0.49 
THY018 BRAF p.Val600Glu c.1799T>A 0.22 
THY019 BRAF p.Val600Glu c.1799T>A 0.43 
THY022 BRAF p.Val600Glu c.1799T>A Man 
THY024 BRAF p.Val600Glu c.1799T>A 0.07 
THY032 BRAF p.Val600Glu c.1799T>A 0.31 
THY038 BRAF p.Val600Glu c.1799T>A 0.36 
THY039 BRAF p.Val600Glu c.1799T>A 0.38 
THY042 BRAF p.Val600Glu c.1799T>A 0.4 
THY043 BRAF p.Val600Glu c.1799T>A Man 
THY046 BRAF p.Val600Glu c.1799T>A 0.23 
THY049 BRAF p.Val600Glu c.1799T>A 0.16 
THY050 BRAF p.Val600Glu c.1799T>A 0.37 
THY035 CDKN2A p.Glu10Ter c.28G>T 0.08 
THY033 DOCK2 p.T459T c.1377G>A 0.29 
THY012 HRAS p.Gln61Lys c.181C>A 0.76 
THY020 HRAS p.Gln61Arg c.182A>G 0.41 
THY021 KRAS p.Gln61Arg c.182A>G 0.39 
THY008 NOTCH1 p.Leu1932Phe c.5796G>T 0.07 
THY045 NOTCH1 p.Ala1135Val c.3404C>T 0.37 
THY049 NOTCH2 p.Ala21Thr c.61G>A 0.12 
THY006 NRAS p.Gln61Arg c.182A>G 0.45 
THY010 NRAS p.Gln61Lys c.181C>A 0.49 
THY028 NRAS p.Gln61Arg c.182A>G 0.54 
THY030 NRAS p.Gln61Arg c.182A>G 0.48 
THY035 NRAS p.Gln61Arg c.182A>G 0.43 
THY036 NRAS p.Gln61Arg c.182A>G 0.39 
THY024 PIK3CA p.Tyr1021His c.3061T>C 0.09 
THY011 PTEN p.Gln110Ter c.328C>T 0.75 
THY045 PTEN p.Asn184fs c.548dupA 0.64 
THY047 PTEN n/a c.634+5G>C 0.62 
THY001 RET p.Met918Thr c.2753T>C 0.45 
THY002 RET p.Glu632_Leu633del c.1894_1899delGAGCTG 0.33 
THY003 RET p.Ala294Gly c.881C>G 0.18 
THY003 RET p.Met918Thr c.2753T>C 0.18 
THY009 RET p.Met918Thr c.2753T>C 0.36 
THY014 RET p.Met918Thr c.2753T>C 0.44 
THY015 RET p.Ala883Ser c.2647GG>TT 0.24 
THY016 RET p.Met918Thr c.2753T>C 0.48 
THY023 RET p.Met918Thr c.2753T>C 0.39 
THY037 RET p.Ala883Ser c.2647GC>TT 0.28 
THY041 RET p.Ser891Ala c.2671T>G 0.21 
THY048 RET p.Met918Thr c.2753T>C 0.67 
THY053 RET   complex indel 0.4 
THY011 TP53 p.Val272Met c.814G>A 0.65 
THY027 TP53 p.Arg337Cys c.1009C>T 0.29 
THY027 TP53 p.Asp281His c.841G>C 0.06 
THY027 TP53 p.Arg248Trp c.742C>T 0.15 
THY033 TP53 p.Arg158His c.473G>A 0.28 
THY045 TP53 p.Arg213Ter c.637C>T 0.63 
THY035 VHL n/a c.*50G>A 0.12 
Supplementary Table 3 – List of detected variants from NGS. TAF: tumour allele frequency, HGVS: Human Genome Variation 
Society annotation. Man: low read number preventing pipeline from calling variant with TAF, but variant seen on manual 
curation and validated with dPCR 
 
 
 
 
 
0 2 0 4 0 6 0 8 0
0
2 0
4 0
6 0
8 0
C o rre la t io n  N G S  V s  d P C R
N G S  T u m o u r A lle le  F re q u e n c y
d
P
C
R
 F
ra
c
ti
o
n
a
l 
A
b
u
n
d
a
n
c
e
R
2
:  0 .9 2
 
Supplementary Figure 1  – Scatter plot illustrating correlation between NGS and dPC 
 
 
 
 
